logo
Where was the Garden of Eden located? Scientist makes shocking new claim

Where was the Garden of Eden located? Scientist makes shocking new claim

Yahoo10-04-2025

Holy plot twist!
A provocative new theory suggests that the original Garden of Eden may not have been in Mesopotamia, roughly modern-day Iraq, as has been long-assumed — but rather in Egypt, under the towering shadow of the much older Great Pyramid of Giza.
Dr. Konstantin Borisov, a computer engineer, is shaking up biblical geography with a study published in the journal Archaeological Discovery, claiming the famed paradise where Adam and Eve once frolicked may have flourished on Egyptian soil.
The Bible describes a river flowing out of Eden that split into four branches — the Gihon, Pishon, Tigris, and Euphrates. Scholars have long assumed Eden was in Iraq, home to the Tigris and Euphrates.
But Borisov claims the ancient rivers could also correspond to the Nile (Gihon), Euphrates, Tigris, and the Indus River (Pishon).
'By examining a map from around 500 BC, it becomes apparent that the only four rivers emerging from the encircling Oceanus are the Nile, Tigris, Euphrates and Indus,' Borisov wrote in his paper.
And he's not stopping there — the scientist claims the sacred Tree of Life itself, said to bear fruit that grants eternal life, once stood near the Great Pyramid.
He believes the pyramid's internal structure even mimics the shape of a tree.
'It cannot be overlooked,' he wrote, 'the charge particles in this simulation are arranged in a way that creates several parallel branches extending outward from the center line, creating a tree-like representation.'
Borisov pointed to simulations from 2012 that modeled the pyramid's King's Chamber, showing charged particles clustering at the peak of the monument — producing light phenomena that resemble a glowing tree.
'While emitted from the pyramid, the charge particles collide with neutral nitrogen and oxygen atoms, leading to their ionization, resulting in the release of photons, predominantly in shades of purple and green,' he wrote.
The 'tree' in his simulation? It has five distinct branches — just like the five layered beams in the pyramid's relieving chambers.
To bolster his theory, Borisov turned to ancient texts and medieval maps — including the 13th-century Hereford Mappa Mundi, which shows a circular Earth ringed by a mythical river called Oceanus. At the map's top is 'Paradise,' nestled beside the river's edge.
Ancient historian Titus Flavius Josephus also backs up parts of Borisov's vision.
In Antiquities of the Jews (Book 1, Chapter 1), Josephus wrote: 'Now the garden was watered by one river, which ran round about the whole earth, and was parted into four parts.'
Josephus also identified the four biblical rivers with real-world equivalents: 'Phison… running into India, makes its exit into the sea… Euphrates also, as well as Tigris, goes down into the Red Sea… and Geon runs through Egypt,' he wrote, noting that Geon (Gihon) is the ancient Greek name for the Nile.
According to Borisov, that means we already have the clues we need.
'At this point, all the rivers of the Bible are identified, and it seems that all we need is to follow the course of the Oceanus River around the globe to pinpoint the location of Eden,' he wrote — though he concedes he still needs to 'determine the precise course of Oceanus.'
Still, if he's right, Egypt's Great Pyramid may not just be a wonder of the ancient world — it could be the last surviving monument of biblical paradise.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology

Yahoo

time3 days ago

  • Yahoo

Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy were published in the international medical journal, Journal of Hematology & Oncology (Impact Factor (IF) = 29.9). Published results include those from the Phase 1 dose-escalation part of the study which evaluated sac-TMT in advanced solid tumors, and those from the Phase 2 expansion cohorts of the study, evaluating sac-TMT in metastatic triple-negative breast . The results of the study demonstrated the therapeutic potential of sac-TMT in this patient population. Results KL264-01/MK-2870-001 is a Phase 1/2 first-in-human trial of sac-TMT as monotherapy in patients who have an unresectable locally advanced or metastatic solid tumor which is refractory to standard therapies, which is a global multi-centre study. Presented results include those from the Phase 1 portion of this study, and the Phase 2 expansion cohorts for TNBC and HR+/HER2– breast cancer. The results of the study showed that sac-TMT demonstrated a manageable safety profile in patients with unresectable locally advanced/metastatic solid tumors and promising antitumor activity in metastatic TNBC and HR+/HER2− breast cancer. Currently, sac-TMT is being investigated in several Phase 3 studies in China, led by the Company, as well as globally, where MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) holds the exclusive rights. In May 2022, the Company licensed the exclusive rights to MSD to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan). About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestically developed and fully approved-for-marketing ADC in China with global intellectual property rights. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the NMPA, and were included in the priority review and approval process. As of today, Kelun-Biotech has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech( a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel DC aseets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Snakes
Snakes

National Geographic

time3 days ago

  • National Geographic

Snakes

There are over 3,000 types of snakes in the world. They have wide distribution, living everywhere except in Antarctica, Iceland, Ireland, Greenland, and New Zealand. In the United States, snakes live in almost every state, except Alaska, Hawaii, and Maine. About 600 species are venomous. Of those, only about 200 can kill or significantly wound a human. Nonvenomous snakes, which range from harmless garter snakes to the not-so-harmless python, dispatch their victims by swallowing them alive or constricting them to death. Whether they kill by striking with venom or squeezing, nearly all snakes eat their food whole, in sometimes astoundingly large portions. Almost all snakes are covered in scales. As reptiles, they're cold blooded and must regulate their body temperature externally. Scales serve several purposes: They trap moisture in arid climates and reduce friction as the snake moves. Several species of snakes are mostly scaleless, but even those have scales on their bellies. Cultural significance of snakes Throughout history, snakes have been important symbols in cultures across the globe. In ancient Egypt, people often associated snakes with royalty. The goddess Wadjet was depicted as a snake. Pharaohs wore head gear and held scepters topped with a uraeus, or the upright form of an Egyptian cobra. Many East Asian cultures see snakes as symbols of immortality and renewal because they can shed their skin. The snake is also one of 12 animals that hold a spot on the Chinese zodiac and star in many folklore. Snakes are also familiar creatures in Native American folk tales and traditions. The Hopi and Cherokee see snakes as connections to the Underworld that deserve reverence and respect. How do snakes hunt? Snakes eat all sorts of animals, from small mammals and small fish to larger prey up to three times larger than the width of their head. They're able to swallow such large animals because their lower jaws unhinge from their upper jaws. Once in a snake's mouth, the prey is held in place by teeth that face inward, trapping it there. Snakes hunt by flicking their forked tongues in different directions to smell their surroundings. That lets them know when danger—or food—is nearby. Snakes have several other ways to detect a snack. Openings called pit holes in front of their eyes sense the heat given off by warm-blooded prey. Bones in their lower jaws pick up vibrations from rodents and other scurrying animals. (Snakes gang up to hunt prey—a first) Left: A green tree python (Morelia viridis) at the Riverside Zoo. Right: Speckled rattlesnake (Crotalus mitchellii) at the Arizona-Sonora Desert Museum. Photographs by Joel Sartore, National Geographic Photo Ark Behavior and reproduction About once a month snakes shed their skin, a process called ecdysis that makes room for growth and gets rid of parasites. They rub against a tree branch or other object, then slither out of their skin head first, leaving it discarded inside-out. Most snakes lay eggs, but some species—like sea snakes—give birth to living young. Very few snakes pay any attention to their eggs, with the exception of pythons, which incubate their eggs. (These are the rules of king cobra fight club—no venom allowed.) Here's a fact to make ophidiophobes feel uneasy: Five species of snakes can fly. Sea snakes Most snakes live on land, but there are about 70 species of snakes that live mostly among the coral reefs in the Indian and Pacific oceans. These family elapidae sea snakes and their cousins, kraits, are some of the most venomous snakes that exist. The yellow bellied sea snake is one of the most venomous. Most sea snakes pose little threat to humans because they're shy, gentle, and their fangs are too short to do much damage. What to do if you see a snake in the wild Experts say it's best to leave snakes alone and give them plenty of room. A rattlesnake (Crotalus) can lunge about two-thirds of its body weight. Most nonvenomous snakes will eventually glide out of the way. If a snake doesn't move, experts say to wait it out or just turn back. Do not attempt to handle it or touch it with a stick. Rattlesnakes don't always rattle their tails in warning, so it's important to be extra careful. (The key to protecting rattlesnakes from extinction? Clearing their name and reputation.) Conservation status There are nine IUCN Red List categories: Not Evaluated, Data Deficient, Least Concern, Near Threatened, Vulnerable, Endangered, Critically Endangered, Extinct in the Wild, and Extinct. Roughly a hundred snake species are endangered, typically due to habitat loss from development. Of those endangered snakes, 17 percent are vipers. Pythons 101 From unbelievably flexible jaws to rows of razor sharp teeth, a range of impressive features make the python one of nature's most formidable predators. Learn about ball, burmese, reticulated, and other types of pythons, what the snakes eat, where they live, and how a surprising feature might be a sign of legged ancestors. What are the top 10 biggest snakes? The 10 biggest snakes in the world are the African rock python (Python sebae), amethystine python (Simalia amethistina), black mamba (Dendroaspis polylepis), boa constrictor, Burmese python (Python bivittatus), green anaconda (Eunectes murinus), Indian python (Python molurus), king brown (Pseudechis australis), king cobra (Ophiophagus hannah), and reticulated python (Malayopython reticulatus). —BBC Science Focus Magazine What are the four most poisonous snakes? India has nearly 60 highly venomous snakes, including a few known as the 'Big Four.' They are the common krait, Russell's viper, saw-scaled viper, and spectacled snake with the deadliest venom in the world is the western or inland taipan. These snakes live in arid and semi-arid regions of Australia. Taipan venom contains a mix of toxins that paralyze muscles, constrict breathing, and cause internal bleeding. —Wildlife S.O.S. and Britannica What will keep snakes away? There are many ways to deter snakes from entering your home or property. Discourage rodents by maintaining a tidy yard and patching any holes or cracks where animals can enter. Keep pet food stored indoors and consider fencing or concrete walls to provide a physical barrier to snakes. Most experts don't recommend chemical repellents, which can be ineffective and harmful to others. Experts also discourage inhumane deterrents such as glue traps and ceramic eggs in chicken coops. —Utah State University How dangerous are snakes? Of the 3,000 species of snakes in the world, only about 10 percent are venomous. Half of those have venom deadly enough to cause human fatalities. —Rainforest Trust This story originally published on January 25, 2019. It was updated on June 10, 2025.

Fraser Institute News Release: AI can help mitigate shrinking labour force by increasing productivity of existing workers and adding new ones
Fraser Institute News Release: AI can help mitigate shrinking labour force by increasing productivity of existing workers and adding new ones

Yahoo

time3 days ago

  • Yahoo

Fraser Institute News Release: AI can help mitigate shrinking labour force by increasing productivity of existing workers and adding new ones

VANCOUVER, BC, June 10, 2025 /CNW/ - As Canada's labour force shrinks due to aging and slowing rates of immigration, artificial intelligence (AI) can help by increasing the number of available workers and improving worker productivity, finds a new study published today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank. "While there's a common perception that AI will eventually lead to mass unemployment, it actually opens the door to the labour market for people who may have been on the outside looking in," said Morley Gunderson, professor emeritus of economics at the University of Toronto and author of Can AI Mitigate Our Labour Force Problems? For example, AI can facilitate more effective job-matching between employers and job seekers including retirees who want to return to work, students who want part-time jobs, and new immigrants. AI can also improve employment prospects for people with disabilities by equipping employees with assistive technologies (screen readers, speech recognition software, etc.) and helping make driverless vehicles, "smart" wheelchairs and other AI-powered resources more widely available. At the same time, AI can help increase productivity growth, which has stagnated in Canada. For example, AI can help connect small and dispersed geographical markets with larger commercial centres, facilitate trade (within Canada and internationally), help small firms grow, and increase the ability of scientists and engineers to develop innovations that fuel productivity growth. "Rather than unduly fearing AI, Canadians should welcome the promise of AI to increase our ability to produce goods and services and improve our living standards," said Steven Globerman, senior fellow at the Fraser Institute. Follow the Fraser Institute on Twitter | Like us on Facebook The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, Montreal, and Halifax and ties to a global network of think-tanks in 87 countries. Its mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. To protect the Institute's independence, it does not accept grants from governments or contracts for research. Visit SOURCE The Fraser Institute View original content to download multimedia:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store